Abstract
Optimal treatment of heart failure (HF) is a continuous challenge. Pharmacological progress, interventional or surgical procedures, kinesio-therapeutic rehabilitation have modestly improved the prognosis of HF with reduced ejection fraction (EF), and patients with HF with preserved EF, or those hospitalized for HF regardless of EF still have a high mortality risk1,2. The association to the standard treatment of HF either of CoQ10 (CoQ10) or selenium has been evaluated over the last 30 years in many small and non-statistical powered studies. The recent publication of randomized trials Q-SYMBYO and Kisel-10 renewed interest in these supplements. The article aims to synthesize literature data on the role and mechanism of action of CoQ10 and selenium in HF as well as the results of the published trials and meta-analyses, focusing on the latest.